Skip to main content

Advertisement

Log in

IL-32 expression is an independent prognostic marker for gastric cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

A strong link between inflammation and gastrointestinal cancer has been demonstrated. Interleukin (IL)-32 is a recently described pro-inflammatory cytokine characterized by the induction of nuclear factor kappa B (NF-κB) activation. We investigated whether IL-32 expression has clinical significance in gastric cancer. A total of 182 gastric cancer patients who received curative gastrectomy were enrolled in our study. IL-32 expression was detected by immunohistochemistry, and the correlation between clinicopathological features and IL-32 expression was analyzed. Tumor depth and lymph node metastases developed more frequently in IL-32-positive gastric cancer patients than those who were negative for IL-32 expression (p < 0.01). Lymphatic- and venous invasion in the IL-32-positive group were more severe than in cancer cells lacking IL-32 expression (p < 0.05). Multivariate analysis demonstrated that IL-32 is one of the prognostic markers (p < 0.03) for gastric cancer, in addition to nodal involvement and tumor depth. IL-32 positivity significantly affected clinicopathological factors. Thus, IL-32 expression in gastric cancer may serve as a preferential metastatic condition that allows cells to escape host antitumor immunity. Pro-inflammatory cytokines induce immunosuppression in a paracrine manner, thereby facilitating the metastasis of tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Noh SH, Hyung WJ, Cheong JH. Minimally invasive treatment for gastric cancer: approaches and selection process. J Surg Oncol. 2005;90:188–93.

    Article  PubMed  Google Scholar 

  2. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol. 1996;23:360–8.

    PubMed  CAS  Google Scholar 

  3. Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Modern surgery for gastric cancer-Japanese perspective. Scand J Surg. 2006;95:232–5.

    PubMed  CAS  Google Scholar 

  4. Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol. 2006;41:929–42.

    Article  PubMed  Google Scholar 

  5. Kobayashi M, Okabayashi T, Sano T, Araki K. Metastatic bone cancer as a recurrence of early gastric cancer: characteristics and possible mechanisms. World J Gastroenterol. 2005;11:5587–91.

    PubMed  Google Scholar 

  6. Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006;24:4347–55.

    Article  PubMed  Google Scholar 

  7. Warneke VS, Behrens HM, Hartmann JT, Held H, Becker T, Schwarz NT, Röcken C. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29:2364–71.

    Article  PubMed  Google Scholar 

  8. Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer. 2010;13:212–21.

    Article  PubMed  CAS  Google Scholar 

  9. Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett. 1995;95:207–12.

    Article  PubMed  CAS  Google Scholar 

  10. Morisaki T, Katano M, Ikubo A, Anan K, Nakamura M, Nakamura K, Sato H, Tanaka M, Torisu M. Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol. 1996;63:234–9.

    Article  PubMed  CAS  Google Scholar 

  11. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

    Article  PubMed  CAS  Google Scholar 

  12. Ben-Baruch A. Inflammation-associated immune suppression incancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52.

    Article  PubMed  CAS  Google Scholar 

  13. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527–36.

    Article  PubMed  CAS  Google Scholar 

  14. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, Sfriso P, Balestro E, Dinarello CA, Saetta M. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:894–901.

    Article  PubMed  CAS  Google Scholar 

  15. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF alpha. Immunity. 2005;22:131–42.

    PubMed  CAS  Google Scholar 

  16. Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev. 2007;6:131–7.

    Article  PubMed  CAS  Google Scholar 

  17. Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med. 2009;180:769–79.

    Article  PubMed  CAS  Google Scholar 

  18. Nishida A, Andoh A, Inatomi O, Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem. 2009;284:17868–76.

    Article  PubMed  CAS  Google Scholar 

  19. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd english edition. Gastric Cancer. 1998;1:10–24.

    Article  PubMed  Google Scholar 

  20. Hong J, Bae S, Kang Y, Yoon D, Bai X, Chan ED, Azam T, Dinarello CA, Lee S, Her E, Rho G, Kim S. Suppressing IL-32 in monocytes impairs the induction of the pro-inflammatory cytokines TNF alpha and IL-1beta. Cytokine. 2010;49:171–6.

    Article  PubMed  CAS  Google Scholar 

  21. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol. 2011;186:3462–71.

    Article  PubMed  CAS  Google Scholar 

  22. Kobayashi H, Lin PC. Molecular characterization of IL-32 in human endothelial cells. Cytokine. 2009;46:351–8.

    Article  PubMed  CAS  Google Scholar 

  23. Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, Kim JH, Kim EJ, Park DK, Kim SH. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol. 2008;18:1606–12.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by Grant-in-Aid for Scientific Research (KAKENHI) (No 21591707). The authors would like to thank the pathologists for their valuable technical assistance and facilitating the collection of patient information.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sumiya Ishigami.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ishigami, S., Arigami, T., Uchikado, Y. et al. IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol 30, 472 (2013). https://doi.org/10.1007/s12032-013-0472-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0472-4

Keywords

Navigation